ES2369547T3 - Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento. - Google Patents
Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento. Download PDFInfo
- Publication number
- ES2369547T3 ES2369547T3 ES06843990T ES06843990T ES2369547T3 ES 2369547 T3 ES2369547 T3 ES 2369547T3 ES 06843990 T ES06843990 T ES 06843990T ES 06843990 T ES06843990 T ES 06843990T ES 2369547 T3 ES2369547 T3 ES 2369547T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- procedure
- patients
- diseases associated
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 29
- 201000010099 disease Diseases 0.000 title claims abstract description 27
- 210000001723 extracellular space Anatomy 0.000 title claims abstract description 12
- 238000011282 treatment Methods 0.000 title claims description 50
- 238000000034 method Methods 0.000 title abstract description 39
- 239000002253 acid Substances 0.000 title 1
- 239000004744 fabric Substances 0.000 title 1
- 108020004414 DNA Proteins 0.000 claims abstract description 31
- 102000053602 DNA Human genes 0.000 claims abstract description 14
- 210000001519 tissue Anatomy 0.000 claims abstract description 13
- 210000000056 organ Anatomy 0.000 claims abstract description 12
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 23
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 23
- 239000003826 tablet Substances 0.000 claims description 23
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 16
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 229940034610 toothpaste Drugs 0.000 claims description 7
- 239000000606 toothpaste Substances 0.000 claims description 7
- 229940112822 chewing gum Drugs 0.000 claims description 6
- 235000015218 chewing gum Nutrition 0.000 claims description 6
- 239000006190 sub-lingual tablet Substances 0.000 claims description 4
- 229940098466 sublingual tablet Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229940100618 rectal suppository Drugs 0.000 claims description 2
- 239000006215 rectal suppository Substances 0.000 claims description 2
- 229940002226 buccal film Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 231100000673 dose–response relationship Toxicity 0.000 abstract description 2
- 230000001839 systemic circulation Effects 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 108010086613 Streptodornase and Streptokinase Proteins 0.000 description 11
- 238000011835 investigation Methods 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 9
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229960001225 rifampicin Drugs 0.000 description 6
- 229960004533 streptodornase Drugs 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010023197 Streptokinase Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 229960005202 streptokinase Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 108010004032 Bromelains Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 208000006503 Amebic Liver Abscess Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 101000863717 Bos taurus Deoxyribonuclease-1 Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010063741 Hepatic amoebiasis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 229940119679 deoxyribonucleases Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU2006/000642 WO2008066403A1 (fr) | 2006-11-28 | 2006-11-28 | Procédé de traitement de maladies humaines accompagnées d'une teneur plus élevée d'adn dans des espaces intercellulaires et préparation médicamenteuse destinée à sa mise en oeuvre |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2369547T3 true ES2369547T3 (es) | 2011-12-01 |
| ES2369547T8 ES2369547T8 (es) | 2012-01-05 |
Family
ID=39468110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06843990T Active ES2369547T3 (es) | 2006-11-28 | 2006-11-28 | Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8871200B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2095825B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5372769B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090087095A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE513557T1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2369547T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL199005A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2095825T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008066403A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006130034A1 (fr) * | 2005-04-25 | 2006-12-07 | Dmitry Dmitrievich Genkin | Procede pour prolonger la duree de vie d'animaux ou de l'humain |
| US8388951B2 (en) * | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| EP2095825B8 (en) | 2006-11-28 | 2012-03-28 | CLS Therapeutics Limited | Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method |
| US20130053595A1 (en) | 2009-09-18 | 2013-02-28 | Arkema France | Catalyst and process for preparing acrolein and/or acrylic acid by dehydration reaction of glycerin |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| US11225648B2 (en) | 2015-01-04 | 2022-01-18 | Protalix Ltd. | Modified DNase and uses thereof |
| CN108289932A (zh) * | 2015-05-22 | 2018-07-17 | D·D·格恩金 | 胞外dna作为神经变性的治疗靶点 |
| BR112018007017B1 (pt) * | 2015-10-07 | 2023-11-28 | Novozymes A/S | Composição detergente, construto de ácido nucleico ou vetor de expressão, uso de um polipeptídeo, célula hospedeira recombinante e método para produzir o polipeptídeo |
| WO2018197547A1 (en) | 2017-04-25 | 2018-11-01 | Lipoxen Technologies Limited | Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i |
| KR20200122320A (ko) | 2018-01-16 | 2020-10-27 | 씨엘에스 테라퓨틱스 리미티드 | 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료 |
| EP3813555A4 (en) | 2018-06-29 | 2022-03-30 | Tets, Viktor, Veniaminovich | COMPOSITIONS FOR MODULATION OF INTESTINAL FLORA |
| US20200046809A1 (en) * | 2018-08-07 | 2020-02-13 | Bradley G. Thompson | Methods for regulating endogenous production of dnase1 |
| WO2020131952A1 (en) * | 2018-12-17 | 2020-06-25 | Mynarcik Dennis C | Compositions and methods for removing dental calculi |
| US12478571B2 (en) | 2018-12-17 | 2025-11-25 | Pontis Biologics, Inc. | Enzyme based compositions and methods for removing dental calculi |
| IL301970A (en) | 2020-10-07 | 2023-06-01 | Protalix Ltd | Long-acting dnase |
| EP4346879A4 (en) * | 2021-05-24 | 2025-04-09 | Peri-Ness Technologies Ltd | Therapeutic regimen with dnase |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3224942A (en) | 1962-01-15 | 1965-12-21 | Rorer Inc William H | Anti-inflammatory, anti-edema and anti-thrombi drug |
| US3324002A (en) | 1962-09-17 | 1967-06-06 | Armour Pharma | Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids |
| JPS5826822A (ja) | 1981-08-10 | 1983-02-17 | Kaken Pharmaceut Co Ltd | 慢性腎炎治療剤 |
| JPS61293927A (ja) * | 1986-06-18 | 1986-12-24 | Kaken Pharmaceut Co Ltd | 肝臓疾患予防治療剤 |
| US4985243A (en) | 1988-01-20 | 1991-01-15 | Ml Technology Ventures, L.P. | Composition and method for protecting against diseases caused by microorganisms |
| ATE358176T1 (de) * | 1988-12-23 | 2007-04-15 | Genentech Inc | Menschliche dnase |
| US5464817A (en) | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
| DE4024530A1 (de) | 1990-08-02 | 1992-02-06 | Klinger & Co Dr | Verfahren zur bekaempfung von viren |
| FR2666096B1 (fr) | 1990-08-21 | 1993-12-31 | Sfri Sa | Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu. |
| EP0599850B1 (en) | 1991-08-16 | 1996-01-10 | Vical, Inc. | Composition and method for treating cystic fibrosis |
| US5484589A (en) * | 1992-04-20 | 1996-01-16 | Rufeld, Inc. | Anti-viral methods using RNAse and DNAse |
| NZ299257A (en) | 1992-06-08 | 2000-08-25 | Genentech Inc | Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase |
| AU7212694A (en) | 1993-06-24 | 1995-01-17 | Rufeld, Inc. | Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i |
| CH686982A5 (fr) | 1993-12-16 | 1996-08-15 | Maurice Stroun | Méthode pour le diagnostic de cancers. |
| RU2099080C1 (ru) | 1994-02-11 | 1997-12-20 | Дмитрий Иванович Финько | Способ предотвращения развития рака |
| ATE268605T1 (de) | 1994-03-04 | 2004-06-15 | Genentech Inc | Pharmazeutische akzeptabel dnase zusammensetzung |
| EP0761683B1 (en) | 1994-05-20 | 2005-02-02 | Hisamitsu Pharmaceutical Co., Inc. | Protein or polypeptide, process for producing the same, and intermediate compound tehrefor |
| JP4118334B2 (ja) | 1996-02-05 | 2008-07-16 | ジェネンテック・インコーポレーテッド | ヒトｄｎアーゼ |
| WO1997034015A1 (en) | 1996-03-15 | 1997-09-18 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays |
| US6391607B1 (en) * | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| US6524578B1 (en) | 1996-07-10 | 2003-02-25 | Scott E. Tackett | Use of nuclease to reduce wrinkles and discolorations in humans |
| US6455250B1 (en) | 1997-12-11 | 2002-09-24 | The Regents Of The University Of California | Endonuclease compositions and methods of use |
| CN1243545C (zh) | 1998-07-16 | 2006-03-01 | 研究发展基金会 | 切割dna的抗肿瘤剂 |
| US6465177B1 (en) | 1998-10-26 | 2002-10-15 | John Wayne Cancer Institute | Detection of loss of heterozygosity in tumor and serum of melanoma patients |
| AU2156600A (en) | 1998-11-25 | 2000-06-13 | Cold Spring Harbor Laboratory | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| ATE369419T1 (de) * | 1999-08-17 | 2007-08-15 | Sei-Ichi Tanuma | Deoxyribonuklease, dafür kodierendes gen und verfahren |
| US6428785B1 (en) | 1999-10-28 | 2002-08-06 | Immunolytics Inc. | Method and composition for treating prostate cancer |
| UA78486C2 (uk) | 1999-12-10 | 2007-04-10 | Хемджен Корпорейшн | Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти) |
| AU4430701A (en) | 2000-04-03 | 2001-10-15 | Antisoma Research Limited | Compounds for targeting |
| RU2202109C1 (ru) | 2001-08-03 | 2003-04-10 | Научно-исследовательский институт неврологии РАН | Способ выявления степени нарушения реологических свойств крови |
| RU2207876C1 (ru) * | 2001-11-08 | 2003-07-10 | Ткаченко Виталий Васильевич | Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия |
| EP1549337B1 (en) * | 2002-02-18 | 2014-08-13 | Ockham Biotech Limited | Combination of DNase I and glycosaminoglycans for use in extracellular DNA clearance |
| RU2207676C1 (ru) | 2002-04-24 | 2003-06-27 | ООО "Предприятие "Контакт-1" | Плоский радиолокационный отражатель |
| DE10221194B4 (de) | 2002-05-13 | 2005-02-10 | Fryda, Waltraud, Dr.med. | Hyaluronidasehaltiges Hautpflegemittel |
| US20040001817A1 (en) | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
| RU2239442C1 (ru) | 2003-05-05 | 2004-11-10 | Красноярская государственная медицинская академия | Способ профилактики внутриутробных инфекций у детей |
| WO2005004904A1 (en) | 2003-07-14 | 2005-01-20 | Dmitry Dmitrievich Genkin | Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants) |
| RU2269356C2 (ru) * | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения онкологических заболеваний |
| RU2269359C2 (ru) | 2004-03-12 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты) |
| US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
| AU2003298972A1 (en) | 2003-07-14 | 2005-02-04 | Dmitry Dmitrievich Genkin | Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| WO2006130034A1 (fr) | 2005-04-25 | 2006-12-07 | Dmitry Dmitrievich Genkin | Procede pour prolonger la duree de vie d'animaux ou de l'humain |
| RU2269358C2 (ru) | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| RU2239404C1 (ru) | 2003-09-17 | 2004-11-10 | Бессонов Дмитрий Михайлович | Способ профилактики старения организма человека |
| RU2267329C2 (ru) | 2004-03-12 | 2006-01-10 | Дмитрий Дмитриевич Генкин | Способ лечения заболеваний, сопровождающихся изменениями качественного и/или количественного состава внеклеточной днк крови (варианты) |
| RU2269357C2 (ru) | 2004-03-12 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ замедления наступления болезненных состояний, связанных с увеличением возраста человека |
| WO2005115444A2 (en) * | 2004-04-14 | 2005-12-08 | Avirid, Inc. | Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases |
| JP3989936B2 (ja) | 2005-04-07 | 2007-10-10 | 進 須永 | 抗腫瘍剤及び新規ｄｎアーゼ |
| CN101278052A (zh) * | 2005-07-18 | 2008-10-01 | 普罗塔里克斯有限公司 | 生物活性大分子的粘膜或肠给药 |
| RU2308968C2 (ru) | 2005-07-19 | 2007-10-27 | Дмитрий Дмитриевич Генкин | Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации |
| CN105664141A (zh) | 2006-10-18 | 2016-06-15 | 派利尼斯有限公司 | 脱氧核糖核酸酶在制备用于治疗男性低生育力的药物中的应用 |
| EP2095825B8 (en) | 2006-11-28 | 2012-03-28 | CLS Therapeutics Limited | Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method |
| GB0922006D0 (en) | 2009-12-17 | 2010-02-03 | Genome Res Ltd | Diagnostic |
| WO2012075506A2 (en) | 2010-12-03 | 2012-06-07 | Beth Israel Deaconess Medical Center, Inc. | Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses |
-
2006
- 2006-11-28 EP EP06843990A patent/EP2095825B8/en active Active
- 2006-11-28 WO PCT/RU2006/000642 patent/WO2008066403A1/ru not_active Ceased
- 2006-11-28 KR KR1020097013352A patent/KR20090087095A/ko not_active Withdrawn
- 2006-11-28 PL PL06843990T patent/PL2095825T3/pl unknown
- 2006-11-28 AT AT06843990T patent/ATE513557T1/de not_active IP Right Cessation
- 2006-11-28 ES ES06843990T patent/ES2369547T3/es active Active
- 2006-11-28 JP JP2009539202A patent/JP5372769B2/ja not_active Expired - Fee Related
- 2006-11-28 US US12/516,440 patent/US8871200B2/en active Active
-
2009
- 2009-05-27 IL IL199005A patent/IL199005A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ATE513557T1 (de) | 2011-07-15 |
| IL199005A (en) | 2012-04-30 |
| JP2010511039A (ja) | 2010-04-08 |
| ES2369547T8 (es) | 2012-01-05 |
| KR20090087095A (ko) | 2009-08-14 |
| US20100061971A1 (en) | 2010-03-11 |
| EP2095825B1 (en) | 2011-06-22 |
| PL2095825T3 (pl) | 2011-12-30 |
| US8871200B2 (en) | 2014-10-28 |
| EP2095825A1 (en) | 2009-09-02 |
| JP5372769B2 (ja) | 2013-12-18 |
| EP2095825B8 (en) | 2012-03-28 |
| WO2008066403A1 (fr) | 2008-06-05 |
| IL199005A0 (en) | 2010-02-17 |
| EP2095825A4 (en) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2369547T3 (es) | Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento. | |
| AU2013235883B2 (en) | Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections | |
| US9987224B2 (en) | Method and system for preventing migraine headaches, cluster headaches and dizziness | |
| ES2747964T3 (es) | Tratamiento con bacteriófagos para infecciones por E. coli | |
| ES2857199T3 (es) | Terapia con fagos de infecciones de Pseudomonas | |
| ES2632367T3 (es) | Composiciones antibacterianas | |
| US20200323679A1 (en) | Method and System to Facilitate the Growth of Desired Bacteria in a Human's Mouth | |
| US20180263808A1 (en) | Method and System for Preventing Migraine Headaches, Cluster Headaches and Dizziness | |
| CN101563100A (zh) | 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标 | |
| ES2602679T3 (es) | Selección y uso de bacterias del ácido láctico para reducir la inflamación provocada por Helicobacter | |
| Suzuki et al. | Periodontopathic bacterium Fusobacterium nucleatum affects matrix metalloproteinase-9 expression in human alveolar epithelial cells and mouse lung | |
| Ren et al. | Oral microbiota in aging and diseases | |
| Roberts et al. | Ciprofloxacin-resistant pseudomonas | |
| Furlaneto et al. | Probiotics during the therapeutic management of periodontitis | |
| Jovanović et al. | The role of candida albicans on the development of stomatitis in patients wearing dentures | |
| Lieberman | Enzymatic Dissolution of Pulmonary Secretions: An in Vitro Study of Sputum from Patients with Cystic Fibrosis of Pancreas | |
| RU2715694C1 (ru) | Фармацевтическая композиция для лечения глазных инфекций, вызванных метициллин-устойчивыми штаммами Staphylococcus aureus, включающая в качестве активного начала N-концевой CHAP-домен эндолизина бактериофага K Staphylococcus aureus | |
| Bhambri | Role of oral microbial flora in health and illness | |
| Chang et al. | The protease interpain A of Prevotella intermedia promotes human OSCC cells proliferation and migration | |
| WO2008035371A2 (en) | Dietary anti-bacterial compositions | |
| Debattista | Phage therapy: where East meets West | |
| TWI548415B (zh) | 狗圍肛腺瘤之治療方法 | |
| Kowalski et al. | What Are the Potential Benefits of Using Bacteriophages in Periodontal Therapy? Antibiotics 2022, 11, 446 | |
| Seifelnasr | A preliminary study evaluating potential probiotic use in endodontics | |
| Jin et al. | Both live and heat-killed Bifidobacterium animalis J-12 alleviated oral ulcer of LVG golden Syrian hamsters by intervening intestinal flora structure |